Bli medlem
Bli medlem

Du är här


Probi: Another study demonstrates that probiotics from Probi can enhance iron absorption among women of childbearing potential

A recently announced mealtime study shows that intake of one of
Probi's bacterial strains, Lactobacillus plantarum DSM 9843, can
increase the absorption of iron, which can reduce the risk of iron
deficiency. Another study has now confirmed this result.

The absorption of iron from capsules with and without Lactobacillus
plantarum DSM 9843, respectively, which was used in the study now
reported, demonstrates the same result as in the mealtime study
announced on 10 June 2014. The conclusion of the two studies is that
intake of freeze-dried Lactobacillus plantarum DSM 9843 in capsule
form can significantly improve the absorption of iron among women of
childbearing potential.

Iron deficiency and low levels of iron are common among children,
adolescents and women of childbearing potential, both in the western
world and in developing countries. This can lead to iron deficiency
anaemia, with decreased cognition and a poorer immune system as a
result. Menstruating women have a considerable need for iron and
often lack a sufficiently high intake of iron and/or eat a diet with
low iron content. When iron deficiency occurs, the body can increase
its absorption of iron, but often not to a degree that is sufficient
for the deficiency to disappear. This means that there is a large
need for products that promote iron absorption. One alternative for
people with iron deficiency is to take medication with a high iron
content, but these often have side-effects in the form of gastric
discomfort. Taking Lactobacillus plantarum DSM 9843 (LP299V®), which
is contained in ProViva, GoodBelly and Probi Mage®, has earlier been
demonstrated to reduce gastric problems.

The study
Women aged 19-45 ate meals with or without a capsule with freeze-dried
Lactobacillus plantarum DSM 9843. The absorption of iron from the
meals was measured using stable iron isotopes. The result of the
study, which was conducted by a research group headed by Lena
Hulthén, professor of clinical nutrition at Gothenburg University,
demonstrated that the absorption of iron from meals containing
Lactobacillus plantarum DSM 9843 was significantly higher than
absorption from meals without probiotic bacteria.

"The results are very encouraging," says Peter Nählstedt, CEO of Probi
AB. "Through two studies with concordant results, we now have
clinical evidence of the product benefits. During the autumn, we will
now be able to focus on preparing a product launch in 2015 in
cooperation with our distributors. There is a great need for a
product with bio-available iron, which is also gentle on the

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86
99 83, e-mail:

Gun-Britt Fransson, Vice President Research & Development, Probi, tel
+46 46 286 89 74 or mobile +46 705 95 73 27, e-mail:

Probi AB is a Swedish publicly traded biotechnology company that
develops effective and well-documented probiotics. Through its
research, Probi has created a strong product portfolio in the
gastrointestinal health and immune system areas. The products are
available to consumers in more than 30 countries worldwide. The
customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments.
Probi had sales of MSEK 102 in 2013. The Probi share is listed on
NASDAQ OMX Stockholm, Small-cap. Probi has approximately 3,500
shareholders.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.